<DOC>
	<DOC>NCT02399410</DOC>
	<brief_summary>The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.</brief_summary>
	<brief_title>Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>biopsy proven adenocarcinoma of the colon or rectum and synchronous or metachronous peritoneal carcinomatosis. absence of systemic disease, with the exception of small, superficial liver metastases, requiring only minor surgery. resectable disease at staging, during laparoscopic evaluation and during exploration for cytoreductive surgery and intraperitoneal chemotherapy. complete macroscopic cytoreduction at the time of surgery (CC0/1) good general health status (Karnofsky index &gt; 70%) expected life expectancy more than 6 months no other malignancy than disease under study serum creatinine &lt; 1.5 mg/dl or a calculated GFR â‰¥ 60 mL/min/1.73 m serum total bilirubin &lt; 1.5 mg/dl platelet count &gt; 100,000/ml hemoglobin &gt; 9g/dl neutrophil granulocytes &gt; 1,500/ml International Normalized Ration (INR) 2 or &lt; 2 Absence of alcohol and/or drug abuse No inclusion in other clinical trials interfering with the study protocol No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol Absence of heart failure (NYHA 2 or &gt; 2) or significant coronary artery disease No pregnancy or breast feeding Adequate contraception in fertile patients No written informed consent tumour in the presence of obstruction evidence of extraabdominal disease or extensive liver metastasis peritoneal cancer index &gt; 25 active bacterial, viral or fungal infection active gastroduodenal ulcer parenchymal liver disease (any stage cirrhosis) uncontrolled diabetes mellitus severe obstructive or restrictive respiratory insufficiency psychiatric pathology capable of affecting comprehension and judgment faculty Known allergy to oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cytoreductive surgery</keyword>
	<keyword>hipec</keyword>
	<keyword>perioperative chemotherapy</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>colorectal surgery</keyword>
</DOC>